| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC9867 | prostaglandin D2（PGD2) inhibitor Featured | A small molecule compound of prostaglandin D2（PGD2) inhibitor. |
|
| DC12213 | AGN 210676 (Simenepag) | AGN 210676 is a selective prostaglandin EP2 agonist extracted from patent US20070203222A1, Compound example 23, has an EC50 of 5 nM. |
|
| DC12230 | AM211 Featured | AM211 is a potent, selective and orally bioavailable prostaglandin D2 (PGD2) receptor type 2 (DP2) antagonist |
|
| DC6310 | AMG 853(AMG853;Vidupiprant) | AMG 853 is novel a CRTH2 and DP Dual Antagonist. |
|
| DC11174 | ASP7657 Featured | ASP7657 (ASP-7657) is a potent, selective, orally active prostaglandin EP4 receptor antagonist with Ki values of 6.02 nM and 2.21 nM for rat and human EP4 receptors, resepctively. |
|
| DC7364 | AT-56 Featured | AT-56 is a selective, competitive, and highly bioavailable inhibitor of lipocalin-type prostaglandin D synthase (L-PGDS) with a Ki value of 75 µM. |
|
| DC7572 | AZD1981 Featured | AZD1981 is a potent, selective CRTh2 (DP2) receptor antagonist with IC50 of 4 nM, showing >1000-fold selectivity over more than 340 other enzymes and receptors, including DP1 |
|
| DCAPI1079 | Bimatoprost Featured | Bimatoprost is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. |
|
| DC10847 | CAY10441（RO1138452） Featured | CAY10441 is a Selective prostacyclin IP receptor antagonist. |
|
| DC12099 | CAY10595 | CAY10595 is a potent CRTH2/DP2 receptor antagonist that binds to the human receptor with a Ki of 10 nM. |
|
| DCAPI1545 | Cloprostenol sodium | Cloprostenol Sodium is a synthetic F series prostaglandin that functions as a potent agonist towards the PGF2αR (FP receptor). It is known that Cloprostenol Sodium is less selective than other agonists such as fluprostenol, however it displays more potenc |
|
| DC9303 | Taprenepag(CP-544326) Featured | CP-544326 is a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma. |
|
| DC11154 | CR6086 | CR6086 (CR-6086) is a potent, selective prostaglandin E2 receptor 4 (EP4) antagonist with Ki of 16.6 nM (hEP4 receptor), inhibits PGE2-stimulated cAMP production with IC50 of 22 nM. |
|
| DC9863 | Dinoprost Featured | Dinoprost(Prostaglandin F2α) is a naturally occurring prostaglandin used in medicine to induce labor and as an abortifacient. |
|
| DC10563 | E-7046 Featured | E7046 is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM, exhibiting anti-tumor activities. |
|
| DC9016 | Etamsylate | Ethamsylate is a haemostatic drug, also inhibits biosynthesis and action of those prostaglandins. |
|
| DC9685 | Evatanepag (CP-533536) Featured | Evatanepag (CP-533536) is an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation with EC50 of 0.3 nM. |
|
| DC11278 | Fevipiprant Featured | Fevipiprant(QAW039) is a selective, potent, reversible competitive CRTh2 antagonist with an in vitro dissociation constant KD value of 1.1nM at the CRTh2 receptor and an IC50 value of 0.44 nM for inhibition of PGD2-induced eosinophil shape change. |
|
| DC8266 | GW-627368X Featured | GW 627368X is a selective prostanoid EP4 receptor competitive antagonist with additional affinity at TP receptors (pKi values are 7.0 and 6.8 in competition radioligand bioassays). |
|
| DC11377 | L-826,266 | L-826,266 is a potent and selective competitive antagonist of the prostaglandin E2 receptor subtype EP3 (Ki = 0.8 nM). |
|
| DC8635 | Latanoprost Featured | Latanoprost is a prodrug (isopropyl ester) of 17-phenyl-13,14-dihydro prostaglandin F2α. |
|
| DC8249 | MF498 | MF498 is a novel and selective E prostanoid receptor 4 (EP4) inhibitor, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis. |
|
| DC1009 | Laropiprant Featured | MK 0524 is a potent, selective DP1 receptor antagonist with Ki values of 0.57 nM and 0.75 µM for the DP1 and DP2 receptors, respectively. |
|
| DC9607 | MK-2894 | MK-2894 is a highly potent and selective second generation EP4 antagonist. |
|
| DC10785 | MK-7246 Featured | MK-7246 is a potent and selective CRTH2 antagonist with a Ki of 2.5±0.5 nM. |
|
| DC11142 | MK-8318 | MK-8318 (MK8318) is a potent, selective, orally available CRTh2 receptor antagonist with Ki of 5 nM, shows nM potency in functional assay (cAMP IC50=8 nM, β-Arrestin IC50=3.5 nM. |
|
| DC10437 | MRE-269 Featured | MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist. |
|
| DC7701 | NVP-QAV680 | NVP-QAV680 is a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases. |
|
| DC11043 | Omidenepag Featured | Omidenepag is a potent, selective agonist human EP2 receptor with binding IC50/EC50 of 10/1.7 nM, >500-fold selectivity over EP1, EP3 and EP4 receptors; Omidenepag is the active form of Omidenepag Isopropyl (OMDI). |
|
| DC11044 | Omidenepag Isopropyl Featured | Omidenepag Isopropyl (DE-117, OMDI) is the prodrug of Omidenepag, which is a potent, selective agonist human EP2 receptor; demonstrates excellent IOP-lowering activities following ocular administration in ocular normotensive monkeys, Omidenepag Isopropyl (OMDI) is a clinical candidate for the treatment of glaucoma. |
|
